Background Indacaterol is a novel, inhaled, once-daily ultra long-acting β 2-agonist (ultra-
LABA) for the treatment of COPD. This study investigated the effect of indacaterol on …

Background Indacaterol is an inhaled long‐acting beta 2‐agonist that is administered once
daily and has been investigated as a treatment for chronic obstructive pulmonary disease …

BACKGROUND: The drug development process can be streamlined by combining the
traditionally separate stages of dose-finding (Phase IIb) and confirmation of efficacy and …

BACKGROUND: Resting inspiratory capacity (IC) reflects static hyperinflation in chronic
obstructive pulmonary disease (COPD). This study compared the effects of formoterol and …

Background Indacaterol is a long-acting beta-2 agonist for once-daily treatment of COPD.
We evaluated the effects of indacaterol 150 μg on lung hyperinflation compared with …

Two, once daily (qd) inhaled bronchodilators are available for the treatment of chronic
obstructive pulmonary disease (COPD): the β2-agonist indacaterol and the anticholinergic …

INTRODUCTION: Indacaterol is a novel inhaled once-daily long-acting beta2-agonist
(LABA) for the maintenance treatment of COPD that has been compared to existing inhaled …

BACKGROUND: Indacaterol is a novel once-daily inhaled β2-agonist in development for the
treatment of patients with asthma or chronic obstructive pulmonary disease. OBJECTIVE: To …

Background Indacaterol is a once-daily long-acting inhaled β 2-agonist indicated for
maintenance treatment of moderate-to-severe chronic obstructive pulmonary disease …

Background: Indacaterol is a novel, once‐daily β2‐agonist in development for the treatment
of asthma and chronic obstructive pulmonary disease. Studies were required to determine …